LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Griffiths, UK
Languages: English
Types: Doctoral thesis
Subjects:

Classified by OpenAIRE into

mesheuropmc: health care economics and organizations, complex mixtures
Haemophilus influenzae type b (Hib) is an infectious bacterium transmitted from person to person through close contact. Hib can cause meningitis, pneumonia and a number of rarer forms of disease, primarily in children less than five years. Hib conjugate vaccines became available during the early 1990s and high-income countries quickly introduced this vaccine into their routine programmes and have now achieved a near disappearance of Hib disease. However, relatively high vaccine prices and uncertainties about Hib disease burden led to a slow uptake in low- and middle-income countries.\ud The aim of this PhD is to fill gaps in knowledge about the value of Hib vaccination, in terms of whether or not it is a cost-effective intervention in low- and middle-income countries. Moreover, since economic evaluation involves gathering evidence about numerous criteria that may be considered in isolation by policy makers, such as vaccine efficacy, disease burden, meningitis sequelae prevalence and cold chain expansion costs, specific objectives are also to address some of the unanswered questions about key inputs and determinants of cost-effectiveness.\ud The framework of the PhD is shaped around a decision-analytic model designed to estimate the cost-utility of Hib vaccination. The methodology, collection and analysis of data inputs needed to populate the model represent a number of sub-studies, which are all contributions to new evidence. These include a meta-analysis of Hib vaccine efficacy, calculation of Disability Adjusted Life Years due to Hib disease, estimation of treatment costs of Hib disease, assessment of productivity costs due to meningitis sequelae, and calculation of systems costs of introducing Hib vaccine. Case studies from two countries are included in the sub-studies; productivity costs of meningitis sequelae are investigated in Senegal and systems costs of Hib vaccine introduction are estimated in Ethiopia. Cost-utility results generated from the decision-analytic model are presented for two low-income countries; India and Uzbekistan, and one middle-income country; Belarus.\ud This PhD thesis is the first attempt to combine evidence on disease burden, costs and impact of Hib vaccine across multiple countries using a consistent framework and comparable input parameters. As a result, new insights into the relative cost-utility in countries with different economic and epidemiological circumstances are obtained.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Griffiths UK, Korczak V, Ayalew D, Yigzaw A, Incremental system costs of introducing combined DTwP-Hepatitis B-Hib vaccine into National Immunization Services in Ethiopia, Vaccine. 2009 Feb 25; 27(9)
    • 2. Griffiths UK, Miners A, Cost-effectiveness of Haemophilus influenza type b vaccine: A systematic review of the literature, Expert Review of Pharmacoeconomics and Outcome Research, 2009 August (4):333-46
    • 3. Griffiths UK, Clark A, Shimanovich V, Glinskaya I, Tursonova,Kim L, Mosina L, Hajjeh, R, Edmond K, Comparative economic evaluation of Haemophilus influenzae type b vaccine in Belarus and Uzbekistan, PLoS One. 2011;6(6)
    • 4. Griffiths UK, Clark A , Gessner B, Miners A, Sanderson C, Sedyaningsih ER, Mulholland K, Efficacy of Haemophilus influenzae type b conjugate vaccines: Systematic review and meta-analysis, Epidemiol Infect. 2012 May 14:1-13. [Epub ahead of print]
    • 5. Griffiths UK, Dieye, Y, Fleming J, Hajjeh, R, Edmond K, Costs of meningitis sequelae in Dakar, Senegal, Pediatr Infect Dis J. 2012 Jun 4. [Epub ahead of print]
    • 1. Ayieko P, Akumu AO, Griffiths UK, English M., The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis, Cost Eff Resour Alloc. 2009 Jan 22;7:3.
    • 2. Edmond K, Clark A, Korczak V, Sanderson C, Griffiths UK, Rudan I. Global and regional risks of disabling sequelae from bacterial meningitis. Lancet Infect Dis. 2010 May;10(5):317-28.
    • 3. Edmond K, Dieye Y, Griffiths UK, Fleming J, Ba O, Diallo N, Mulholland K, Prospective Cohort Study of Disabling Sequelae and Quality of Life in Children With Bacterial Meningitis in Urban Senegal, Pediatr Infect Dis J. 2010 Nov;29(11):1023-9
    • 4. Ojo LR, O'Loughlin RE, Cohen AL, Edmond KM, Shetty SS, Bear AP, Loo JD, Privor-Dumm L, Griffiths UK, Zuber PLF, Mayers GF,Hajjeh RA, Global Use of Haemophilus influenzae type b conjugate vaccine, Vaccine. 2010 Oct 8;28(43):7117-22
    • 5. Hajjeh RA, Privor-Dumm L, Edmond K, O'Loughlin R, Shetty S, Griffiths UK, Bear AP, Cohen AL, Chandran A, Schuchat A, Mulholland EK, Santosham M, Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine. 2010 Oct 8;28(43):7123-9.
    • 6. Temple B, Griffiths UK, Mulholland EK, RatunFT, Tikoduadua L, Russell FM, The cost of outpatient pneumonia in children less than five years of age in Fiji, Trop Med & Int Health, 2011 Oct 18 [Epub ahead of print]
    • 7. Sinha A, Kim S, Ginsberg G, Franklin H, Kohberger R, Strutton D, Madhi SA, Griffiths UK, Klugman KP, Economic burden of acute lower respiratory infection among children in South Africa, Paediatr Int Child Health, 2012;32(2):65-73
    • 8. Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ, National decision-making on adopting new vaccines: a systematic review, Health Policy Plan. 2012 May;27 Suppl 2:ii5-16
    • 9. Burchett HE, Mounier-Jack S, Griffiths, UK, Biellik R, Chavez E, Haribondhu S, Jasim U., Konate M, Kitaw Y, Molla M, Ongolo-Zogo P, Wakasiaka S, Gilson L, Mills A, New Vaccine Adoption: Qualitative Study of National Decision-Making Processes in Seven Low- and Middle-Income Countries, Health Policy Plan. 2012 May;27 Suppl 2:ii5-16.
    • 230. Ishiwada N, Cao LD, and Kohno Y, PCR-based capsular serotype determination of Haemophilus influenzae strains recovered from Japanese paediatric patients with invasive infection. Clin Microbiol Infect, 2004. 10(10): p. 895-8.
    • 231. Anglaret X, Buissonniere RF, Duval P, Morlat C, and Menager C, Invasive Haemophilus influenzae disease of Melanesian and Caucasian children in New Caledonia. Pediatr Infect Dis J, 1993. 12(10): p. 888-9.
    • 232. Gilbert GL, Johnson PD, and Clements DA, Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health, 1995. 31(2): p. 99- 104.
    • 233. Baraff LJ, Lee SI, and Schriger DL, Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J, 1993. 12(5): p. 389-94.
    • 234. de Jonge RC, van Furth AM, Wassenaar M, Gemke RJ, and Terwee CB, Predicting sequelae and death after bacterial meningitis in childhood: a systematic review of prognostic studies. BMC Infect Dis. 10: p. 232.
    • 235. Edmond K, Clark A, Korczak V, Sanderson C, Griffiths U, and Rudan I, Global and regional risks of disabling sequelae from bacterial meningitis. Lancet Infectious Diseases, 2010. 10(5): p. 317-28.
    • 236. Chang CJ, Chang HW, Chang WN, Huang LT, Huang SC, Chang YC, Hung PL, Chang CS, Chuang YC, Huang CR, Tsai NW, Tsui HW, Wang KW, and Lu CH, Seizures complicating infantile and childhood bacterial meningitis. Pediatr Neurol, 2004. 31(3): p. 165-71.
    • 237. Rasmussen N, Johnsen NJ, and Bohr VA, Otologic sequelae after pneumococcal meningitis: a survey of 164 consecutive cases with a follow-up of 94 survivors. Laryngoscope, 1991. 101(8): p. 876-82.
    • 238. Glinskaya IN GF, Chistenko GN, Fissenko ЕG, Levshina NN, Ushakevich IG, Nekrassova ОV, Grinevich ОV. Features of Hib infection epidemic process in Minsk City before immunization. in 2nd Russian Conference on Actual Problems of Meningococcal Infection and Purulent Meningitis, 2008. Moscow.
    • 239. Gupta V, Hearing evaluation in children with bacterial meningitis. Indian Pediatr, 1993. 30(10): p. 1175-9.
    • 240. Chinchankar N, Mane M, Bhave S, Bapat S, Bavdekar A, Pandit A, Niphadkar KB, Dutta A, and Leboulleux D, Diagnosis and outcome of acute bacterial meningitis in early childhood. Indian Pediatr, 2002. 39(10): p. 914-21.
    • 241. George CN, Letha S, and Bai SS, A clinical study of chronic morbidity in children following pyogenic meningitis. Indian Pediatr, 2002. 39(7): p. 663-7.
    • 282. Lydon P. New Vaccines Introduction Grant. in GAVI Alliance Board Meeting presentation. 2007. Geneva: GAVI Alliance and WHO.
    • 283. GAVI Alliance, GAVI Alliance & Fund Board Meeting, Geneva, Switzerland, 11 & 12 May 2007, FINAL Summary Report. 2007: Geneva
    • 284. Wilson P, Giving developing countries the best shot: An overview of vaccine access and R&D. 2010: Oxam International and Médecins Sans Frontières
    • 285. Maggon K, Industrial R&D paradigm shift to vaccines. Biotechnology Journal, 2009. 4(4): p. 458-461.
    • 286. Sheridan C, Vaccine Market Boosters. Nature Biotechnology, 2009. 27(6): p. 499- 501.
    • 287. Milstien JB and Kaddar M, The role of emerging manufacturers in access to innovative vaccines of public health importance. Vaccine, 2010. 28(9): p. 2115-21.
    • 288. International AIDS Vaccine Initiative, Procurement and Pricing of New Vaccines for Developing Countries. Policy Brief, 2008
    • 289. International AIDS Vaccine Initiative Policy Brief, Procurement and Pricing of New Vaccines for Developing Countries. 2008
    • 290. Danovaro-Holliday MC, Garcia S, de Quadros C, Tambini G, and Andrus JK, Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med, 2008. 5(4): p. e87.
    • 291. WHO, Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies, Expert committee on biological standardization, 2010: Geneva http://www.who.int/immunization_standards/vaccine_quality/who_bs_2155_vac cine_prequalification_revised_procedure_ecbs_endorsed.pdf
    • 292. International AIDS Vaccine Initiative, Procurement and pricing for new vaccines in developing countries. 2008
    • 293. Milstien J, Munira SL, and McKinney SL, Issues in selection of DTwP-based combination vaccines. Vaccine, 2003. 21(15): p. 1658-64.
    • 294. WHO, Proper handling and reconstitution of vaccines avoids programme errors Vaccines and Biologicals Update, 2000. 34(http://www.who.int/vaccinesdocuments/DoxNews/updates/updat34e.pdf).
    • 295. WHO, WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Weekly Epidemiological Record, 2006. 81: p. 445-452.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    61
    61%
  • No similar publications.

Share - Bookmark

Download from

Cite this article